(Q37086162)

18 August 2017

1 reference

title

Managing relapsed and refractory Hodgkin lymphoma (English)

1 reference

18 August 2017

Pauline Brice

1

1 reference

18 August 2017

language of work or name

English

0 references

publication date

12 February 2008

1 reference

British Journal of Haematology

18 August 2017

published in

1 reference

18 August 2017

volume

141

1 reference

18 August 2017

issue

1

1 reference

18 August 2017

page(s)

3-13

1 reference

Involved-field radiotherapy for advanced Hodgkin's lymphoma.

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Second autologous stem cell transplant for multiply relapsed Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in pat

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Radiolabeled immunoglobulin therapy in patients with Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.06998.X

10.1111/J.1365-2141.2008.06998.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference